Status:
COMPLETED
Anti-Inflammatory Effects of Pioglitazone
Lead Sponsor:
Kurume University
Conditions:
Impaired Glucose Tolerance
Type 2 Diabetes Mellitus
Eligibility:
All Genders
35-85 years
Phase:
NA
Brief Summary
There is increasing evidence that inflammation plays a role in progression and destabilization of atherosclerotic plaque. FDG-PET can visualize activated metabolic activity of inflammatory cells. It i...
Detailed Description
Atherosclerotic patients with impaired glucose tolerance and type 2 diabetes will undergo the FDG-PET/CT imaging at baseline and again following 4 months after treatment. Patients who meet eligibility...
Eligibility Criteria
Inclusion
- Subjects between the ages of 35 and 85 years
- Subjects with impaired glucose tolerance and type 2 diabetes, who had atherosclerosis detected by carotid ultrasound and/or CT
- Subjects who had vascular FDG uptake by FDG-PET
Exclusion
- Subjects with insulin treatment
- Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease
- Subjects taking more than three antidiabetic medications
- Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones (TZDs) within 8 weeks prior to randomization
- Subjects with cardiac failure (New York Heart Association Class \> III) or left ventricular dysfunction (LVEF \< 40%)
- Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00722631
Start Date
May 1 2007
End Date
April 1 2012
Last Update
September 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kurume University Hospital
Kurume, Japan, 830-0011